Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for Ventricular Remodeling After Acute Myocardial Infarction
ChiCTR2100049019Phase 4Not yet recruiting
- Sponsor
- Hunan Provincial People's Hospital
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in myocardial infarction (MI) and left ventricular systolic dysfunction (LVSD) (2 arms), sponsored by Hunan Provincial People's Hospital. Primary endpoints: Left ventricular end-diastolic volume and Left ventricular ejection fraction. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
myocardial infarction (MI)left ventricular systolic dysfunction (LVSD)
Beyond the preview
Go deeper on ChiCTR2100049019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049019.